Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05773859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Study acronym: NEODOC
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 18, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2025 to Mar 2026
    • Study completion date: Oct 2025 to Dec 31, 2026
    • Secondary endpoints revised (4)
    • Eligibility criteria shortened, about 2 words
    v5
  2. Eligibility criteria expanded, about 45 wordsv4
  3. Primary and study completion dates: Oct 2024 to Oct 2025
    • Secondary endpoints: details revised at 2 of 4 entries
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2023 to Mar 17, 2023
    • Secondary endpoints revised (4)
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.
Trial Details
NCT Number NCT05773859
Lead Sponsor Radboud University Medical Center
Conditions
(from sponsor)		 Epithelial Ovarian Cancer, Ovarian Carcinoma
Related terms Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov